Polymersome-stabilized doxorubicin-lipiodol emulsions for high-efficacy chemoembolization therapy

Ultrastable Iodinated Oil-Based Pickering Emulsion Enables Locoregional Sustained Codelivery of Hypoxia Inducible Factor-1 Inhibitor and Anticancer Drugs for Tumor Combination Chemotherapy

“…The conventional IO-based emulsion possesses great characteristics such as high loading capability of hydrophilic drugs, excellent radiopacity, as well as good deposition in tumors. However, such an oil-based emulsion is unstable but presents rapid phase separation leading to burst release of cytotoxic drugs that hampers tumor retention time and therapeutic efficacy. , Here, we circumvented the challenge by fabricating ultrastable IO-based emulsion, which was stabilized with silica nanoparticles to form a PE system. We choose silica nanoparticles as a stabilizer for PE due to their excellent biocompatibility, simple synthetic procedure, and great control of the particle size and surface functionalities .…”

“…In this study, we aimed to develop an ultrastable IO-based W/O PE to obtain sustained combinatory delivery of HIF-1 inhibitors and anticancer agents for locoregional treatment of solid tumors. Iodinated oil (also known as ethiodized oil) is an oily contrast medium derived from poppy seed oil, which is widely used as liquid embolic agent by mixing with aqueous solution of antitumor drugs for TACE treatment. , Due to physical instability of conventional IO-based emulsions, biocompatible nanoparticles can be used as stabilizers to develop stable PE, greatly reducing the initial drug burst and enhancing long-term anticancer efficacy. ,− Herein, we prepared hydrophobic silica nanoparticles (HSNs) as the stabilizers to generate a highly stable IO-based W/O PE for locally extended codelivery of HIF-1 inhibitor of ACF with the chemotherapeutic drug doxorubicin (DOX) to achieve a synergistic therapy for tumor treatment (Figure ). Both ACF and DOX were dissolved in the aqueous phase of the emulsion, and HSNs were absorbed in the water–oil interface to resist coalescence (Figure A).…”

Uplifting Antitumor Immunotherapy with Lymph‐Node‐Targeted and Ratio‐Controlled Codelivery of Tumor Cell Lysate and Adjuvant

“…Once PNVs are uptaken by DCs, the disulfide bonds dissociate in response to the reducing cytosol environment and rapidly release TCL and CpG to enhance DC priming. [21] All these properties allowed PNVs to generate potent antitumor efficacies. CpG/TCL@PNVs cured 85% mice in subcutaneous melanoma model, elicited 40% CR in lung metastasis model, and protected 100% cured mice from tumor recurrence.…”

Enumeration and Characterization of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization

“…TACE is a minimally invasive radiological procedure during which a chemotherapeutic agent is directly infused into the main arterial supplier of the tumor, followed by the occlusion of the involved vessel with 100-500 micron-sized embolic particles. In recent years, promising new technological advances have been developed, aimed at improving the stability of pharmaceutical agents and the clinical performance of TACE [15,16]. Currently, radiological response one month after the procedure may be achieved in the majority of patients, but tumor recurrence is almost universal, conditioning a modest survival benefit ranging from 20 to 36 months [17].…”